Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 404K) PPT slides of all figures Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Yee, C. Articles by Greenberg, P. D. Search for Related Content PubMed PubMed Citation Articles by Yee, C. Articles by Greenberg, P. D. Social Bookmarking                            What's this?

Brief Definitive Report

Cassian Yee^a,b, John A. Thompson^b, Patrick Roche^d, David R. Byrd^c, Peter P. Lee^e, Michael Piepkorn^b, Karla Kenyon^a, Mark M. Davis^e, Stanley R. Riddell^a,b, and Philip D. Greenberg^a,b

^a Clinical Research Division, Fred Hutchinson Cancer Research Center, the
^b Department of Medicine, University of Washington, Seattle, Washington 98109
^c Department of Surgery, University of Washington, Seattle, Washington 98109
^d Department of Pathology, Mayo Clinic, Rochester, Minnesota 55905
^e Department of Microbiology and Immunology, Stanford University, Stanford, California 94305
the Fred Hutchinson Cancer Research Center, D3-100, 1100 Fairview Ave. N., Seattle, WA 98109.206-667-7983206-667-6287

cyee{at}fhcrc.org

Current strategies for the immunotherapy of melanoma include augmentation of the immune response to tumor antigens represented by melanosomal proteins such as tyrosinase, gp100, and MART-1. The possibility that intentional targeting of tumor antigens representing normal proteins can result in autoimmune toxicity has been postulated but never demonstrated previously in humans. In this study, we describe a patient with metastatic melanoma who developed inflammatory lesions circumscribing pigmented areas of skin after an infusion of MART-1–specific CD8⁺ T cell clones. Analysis of the infiltrating lymphocytes in skin and tumor biopsies using T cell–specific peptide–major histocompatibility complex tetramers demonstrated a localized predominance of MART-1–specific CD8⁺ T cells (>28% of all CD8 T cells) that was identical to the infused clones (as confirmed by sequencing of the complementarity-determining region 3). In contrast to skin biopsies obtained from the patient before T cell infusion, postinfusion biopsies demonstrated loss of MART-1 expression, evidence of melanocyte damage, and the complete absence of melanocytes in affected regions of the skin. This study provides, for the first time, direct evidence in humans that antigen-specific immunotherapy can target not only antigen-positive tumor cells in vivo but also normal tissues expressing the shared tumor antigen.

Key Words: immunotherapy • melanoma • autoimmunity • vitiligo • T lymphocytes

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

• Shafer-Weaver, K. A., Watkins, S. K., Anderson, M. J., Draper, L. J., Malyguine, A., Alvord, W. G., Greenberg, N. M., Hurwitz, A. A. (2009). Immunity to Murine Prostatic Tumors: Continuous Provision of T-Cell Help Prevents CD8 T-Cell Tolerance and Activates Tumor-Infiltrating Dendritic Cells. Cancer Res. 69: 6256-6264 [Abstract] [Full Text]  
• Mackensen, A. (2009). Adoptive Transfer of Tumor Antigen-specific CD8+ T-cells to Patients with Melanoma: Strategies to Improve Therapeutic Efficacy. Am Soc Clin Oncol Ed Book 2009: 521-524 [Abstract] [Full Text]  
• King, J., Waxman, J., Stauss, H. (2008). Advances in tumour immunotherapy. QJM 101: 675-683 [Abstract] [Full Text]  
• Palmer, D. C., Chan, C.-C., Gattinoni, L., Wrzesinski, C., Paulos, C. M., Hinrichs, C. S., Powell, D. J. Jr., Klebanoff, C. A., Finkelstein, S. E., Fariss, R. N., Yu, Z., Nussenblatt, R. B., Rosenberg, S. A., Restifo, N. P. (2008). From the Cover: Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc. Natl. Acad. Sci. USA 105: 8061-8066 [Abstract] [Full Text]  
• Kieback, E., Charo, J., Sommermeyer, D., Blankenstein, T., Uckert, W. (2008). A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc. Natl. Acad. Sci. USA 105: 623-628 [Abstract] [Full Text]  
• Domchek, S. M., Recio, A., Mick, R., Clark, C. E., Carpenter, E. L., Fox, K. R., DeMichele, A., Schuchter, L. M., Leibowitz, M. S., Wexler, M. H., Vance, B. A., Beatty, G. L., Veloso, E., Feldman, M. D., Vonderheide, R. H. (2007). Telomerase-Specific T-Cell Immunity in Breast Cancer: Effect of Vaccination on Tumor Immunosurveillance. Cancer Res. 67: 10546-10555 [Abstract] [Full Text]  
• Nichols, L. A., Chen, Y., Colella, T. A., Bennett, C. L., Clausen, B. E., Engelhard, V. H. (2007). Deletional Self-Tolerance to a Melanocyte/Melanoma Antigen Derived from Tyrosinase Is Mediated by a Radio-Resistant Cell in Peripheral and Mesenteric Lymph Nodes. J. Immunol. 179: 993-1003 [Abstract] [Full Text]  
• Morimoto, J., Tan, X., Teague, R. M., Ohlen, C., Greenberg, P. D. (2007). Induction of Tolerance in CD8+ T Cells to a Transgenic Autoantigen Expressed in the Liver Does Not Require Cross-Presentation. J. Immunol. 178: 6849-6860 [Abstract] [Full Text]  
• Walton, S. M., Gerlinger, M., de la Rosa, O., Nuber, N., Knights, A., Gati, A., Laumer, M., Strauss, L., Exner, C., Schafer, N., Urosevic, M., Dummer, R., Tiercy, J.-M., Mackensen, A., Jaeger, E., Levy, F., Knuth, A., Jager, D., Zippelius, A. (2006). Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients. J. Immunol. 177: 8212-8218 [Abstract] [Full Text]  
• Berger, C., Flowers, M. E., Warren, E. H., Riddell, S. R. (2006). Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107: 2294-2302 [Abstract] [Full Text]  
• Luiten, R. M., Kueter, E. W.M., Mooi, W., Gallee, M. P.W., Rankin, E. M., Gerritsen, W. R., Clift, S. M., Nooijen, W. J., Weder, P., van de Kasteele, W. F., Sein, J., van den Berk, P. C.M., Nieweg, O. E., Berns, A. M., Spits, H., de Gast, G. C. (2005). Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumor Cells in Metastatic Melanoma Patients. JCO 23: 8978-8991 [Abstract] [Full Text]  
• Sicard, H., Ingoure, S., Luciani, B., Serraz, C., Fournie, J.-J., Bonneville, M., Tiollier, J., Romagne, F. (2005). In Vivo Immunomanipulation of V{gamma}9V{delta}2 T Cells with a Synthetic Phosphoantigen in a Preclinical Nonhuman Primate Model. J. Immunol. 175: 5471-5480 [Abstract] [Full Text]  
• Boonman, Z. F. H. M., van Mierlo, G. J. D., Fransen, M. F., de Keizer, R. J. W., Jager, M. J., Melief, C. J. M., Toes, R. E. M. (2005). Maintenance of Immune Tolerance Depends on Normal Tissue Homeostasis. J. Immunol. 175: 4247-4254 [Abstract] [Full Text]  
• Vignard, V., Lemercier, B., Lim, A., Pandolfino, M.-C., Guilloux, Y., Khammari, A., Rabu, C., Echasserieau, K., Lang, F., Gougeon, M.-L., Dreno, B., Jotereau, F., Labarriere, N. (2005). Adoptive Transfer of Tumor-Reactive Melan-A-Specific CTL Clones in Melanoma Patients Is Followed by Increased Frequencies of Additional Melan-A-Specific T Cells. J. Immunol. 175: 4797-4805 [Abstract] [Full Text]  
• Straathof, K. C., Leen, A. M., Buza, E. L., Taylor, G., Huls, M. H., Heslop, H. E., Rooney, C. M., Bollard, C. M. (2005). Characterization of Latent Membrane Protein 2 Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma. J. Immunol. 175: 4137-4147 [Abstract] [Full Text]  
• Ernstoff, M. S. (2005). Self-Recognition and Tumor Response to Immunotherapy. JCO 23: 5875-5877 [Full Text]  
• Andersen, M. H., Reker, S., Kvistborg, P., Becker, J. C., Straten, P. t. (2005). Spontaneous Immunity against Bcl-xL in Cancer Patients. J. Immunol. 175: 2709-2714 [Abstract] [Full Text]  
• Godefroy, E., Moreau-Aubry, A., Diez, E., Dreno, B., Jotereau, F., Guilloux, Y. (2005). {alpha}v{beta}3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen. JEM 202: 61-72 [Abstract] [Full Text]  
• Dupont, J., Latouche, J.-B., Ma, C., Sadelain, M. (2005). Artificial Antigen-Presenting Cells Transduced with Telomerase Efficiently Expand Epitope-Specific, Human Leukocyte Antigen-Restricted Cytotoxic T Cells. Cancer Res. 65: 5417-5427 [Abstract] [Full Text]  
• Morris, E. C., Tsallios, A., Bendle, G. M., Xue, S.-a., Stauss, H. J. (2005). A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc. Natl. Acad. Sci. USA 102: 7934-7939 [Abstract] [Full Text]  
• O'Mara, L. A., Norian, L. A., Kreamalmeyer, D., White, J. M., Allen, P. M. (2005). T Cell-Mediated Delay of Spontaneous Mammary Tumor Onset: Increased Efficacy with In Vivo versus In Vitro Activation. J. Immunol. 174: 4662-4669 [Abstract] [Full Text]  
• Di Nicola, M., Carlo-Stella, C., Mortarini, R., Baldassari, P., Guidetti, A., Gallino, G. F., Del Vecchio, M., Ravagnani, F., Magni, M., Chaplin, P., Cascinelli, N., Parmiani, G., Gianni, A. M., Anichini, A. (2004). Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination: A Phase I Trial in Metastatic Melanoma. Clin. Cancer Res. 10: 5381-5390 [Abstract] [Full Text]  
• Finkelstein, S. E., Heimann, D. M., Klebanoff, C. A., Antony, P. A., Gattinoni, L., Hinrichs, C. S., Hwang, L. N., Palmer, D. C., Spiess, P. J., Surman, D. R., Wrzesiniski, C., Yu, Z., Rosenberg, S. A., Restifo, N. P. (2004). Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. J. Leukoc. Biol. 76: 333-337 [Abstract] [Full Text]  
• van Oijen, M., Bins, A., Elias, S., Sein, J., Weder, P., de Gast, G., Mallo, H., Gallee, M., van Tinteren, H., Schumacher, T., Haanen, J. (2004). On the Role of Melanoma-Specific CD8+ T-Cell Immunity in Disease Progression of Advanced-Stage Melanoma Patients. Clin. Cancer Res. 10: 4754-4760 [Abstract] [Full Text]  
• Mihalyo, M. A., Doody, A. D. H., McAleer, J. P., Nowak, E. C., Long, M., Yang, Y., Adler, A. J. (2004). In Vivo Cyclophosphamide and IL-2 Treatment Impedes Self-Antigen-Induced Effector CD4 Cell Tolerization: Implications for Adoptive Immunotherapy. J. Immunol. 172: 5338-5345 [Abstract] [Full Text]  
• Mapara, M. Y., Sykes, M. (2004). Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance. JCO 22: 1136-1151 [Abstract] [Full Text]  
• Friedman, R. S., Bangur, C. S., Zasloff, E. J., Fan, L., Wang, T., Watanabe, Y., Kalos, M. (2004). Molecular and Immunological Evaluation of the Transcription Factor SOX-4 as a Lung Tumor Vaccine Antigen. J. Immunol. 172: 3319-3327 [Abstract] [Full Text]  
• Lengagne, R., Le Gal, F.-A., Garcette, M., Fiette, L., Ave, P., Kato, M., Briand, J.-P., Massot, C., Nakashima, I., Renia, L., Guillet, J.-G., Prevost-Blondel, A. (2004). Spontaneous Vitiligo in an Animal Model for Human Melanoma: Role of Tumor-specific CD8+ T Cells. Cancer Res. 64: 1496-1501 [Abstract] [Full Text]  
• Berger, C., Blau, C. A., Huang, M.-L., Iuliucci, J. D., Dalgarno, D. C., Gaschet, J., Heimfeld, S., Clackson, T., Riddell, S. R. (2004). Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood 103: 1261-1269 [Abstract] [Full Text]  
• Vonderheide, R. H., Domchek, S. M., Schultze, J. L., George, D. J., Hoar, K. M., Chen, D.-Y., Stephans, K. F., Masutomi, K., Loda, M., Xia, Z., Anderson, K. S., Hahn, W. C., Nadler, L. M. (2004). Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes. Clin. Cancer Res. 10: 828-839 [Abstract] [Full Text]  
• Dobrzanski, M. J., Reome, J. B., Hollenbaugh, J. A., Dutton, R. W. (2004). Tc1 and Tc2 Effector Cell Therapy Elicit Long-Term Tumor Immunity by Contrasting Mechanisms That Result in Complementary Endogenous Type 1 Antitumor Responses. J. Immunol. 172: 1380-1390 [Abstract] [Full Text]  
• Dobrzanski, M. J., Reome, J. B., Hollenbaugh, J. A., Hylind, J. C., Dutton, R. W. (2004). Effector Cell-Derived Lymphotoxin {alpha} and Fas Ligand, but not Perforin, Promote Tc1 and Tc2 Effector Cell-Mediated Tumor Therapy in Established Pulmonary Metastases. Cancer Res. 64: 406-414 [Abstract] [Full Text]  
• Topp, M. S., Riddell, S. R., Akatsuka, Y., Jensen, M. C., Blattman, J. N., Greenberg, P. D. (2003). Restoration of CD28 Expression in CD28- CD8+ Memory Effector T Cells Reconstitutes Antigen-induced IL-2 Production. JEM 198: 947-955 [Abstract] [Full Text]  
• Matsui, K., O'Mara, L. A., Allen, P. M. (2003). Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. Int Immunol 15: 797-805 [Abstract] [Full Text]  
• Crittenden, M., Gough, M., Chester, J., Kottke, T., Thompson, J., Ruchatz, A., Clackson, T., Cosset, F. L., Chong, H., Diaz, R. M., Harrington, K., Alvarez Vallina, L., Vile, R. (2003). Pharmacologically Regulated Production of Targeted Retrovirus from T Cells for Systemic Antitumor Gene Therapy. Cancer Res. 63: 3173-3180 [Abstract] [Full Text]  
• Ng-Cashin, J., Kuhns, J. J., Burkett, S. E., Powderly, J. D., Craven, R. R., van Deventer, H. W., Kirby, S. L., Serody, J. S. (2003). Host Absence of CCR5 Potentiates Dendritic Cell Vaccination. J. Immunol. 170: 4201-4208 [Abstract] [Full Text]  
• Durda, P. J., Dunn, I. S., Rose, L. B., Butera, D., Benson, E. M., Pandolfi, F., Kurnick, J. T. (2003). Induction of "Antigen Silencing" in Melanomas by Oncostatin M: Down-Modulation of Melanocyte Antigen Expression. Mol Cancer Res 1: 411-419 [Abstract] [Full Text]  
• Meidenbauer, N., Marienhagen, J., Laumer, M., Vogl, S., Heymann, J., Andreesen, R., Mackensen, A. (2003). Survival and Tumor Localization of Adoptively Transferred Melan-A-Specific T Cells in Melanoma Patients. J. Immunol. 170: 2161-2169 [Abstract] [Full Text]  
• Davis, I. D., Jefford, M., Parente, P., Cebon, J. (2003). Rational approaches to human cancer immunotherapy. J. Leukoc. Biol. 73: 3-29 [Abstract] [Full Text]  
• Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E., Greenberg, P. D. (2002). Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173 [Abstract] [Full Text]  
• Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., Robinson, M. R., Raffeld, M., Duray, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., Mavroukakis, S. A., White, D. E., Rosenberg, S. A. (2002). Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes. Science 298: 850-854 [Abstract] [Full Text]  
• Weinschenk, T., Gouttefangeas, C., Schirle, M., Obermayr, F., Walter, S., Schoor, O., Kurek, R., Loeser, W., Bichler, K.-H., Wernet, D., Stevanovic, S., Rammensee, H.-G. (2002). Integrated Functional Genomics Approach for the Design of Patient-individual Antitumor Vaccines. Cancer Res. 62: 5818-5827 [Abstract] [Full Text]  
• Dhodapkar, M. V., Krasovsky, J., Olson, K. (2002). T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc. Natl. Acad. Sci. USA 99: 13009-13013 [Abstract] [Full Text]  
• Dermime, S., Armstrong, A., Hawkins, R. E, Stern, P. L (2002). Cancer vaccines and immunotherapy. Br Med Bull 62: 149-162 [Abstract] [Full Text]  
• Tsao, H., Millman, P., Linette, G. P., Hodi, F. S., Sober, A. J., Goldberg, M. A., Haluska, F. G. (2002). Hypopigmentation Associated With an Adenovirus-Mediated gp100/MART-1-Transduced Dendritic Cell Vaccine for Metastatic Melanoma. Arch Dermatol 138: 799-802 [Abstract] [Full Text]  
• Hodi, F. S., Schmollinger, J. C., Soiffer, R. J., Salgia, R., Lynch, T., Ritz, J., Alyea, E. P., Yang, J., Neuberg, D., Mihm, M., Dranoff, G. (2002). ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc. Natl. Acad. Sci. USA 99: 6919-6924 [Abstract] [Full Text]  
• zum Buschenfelde, C. M., Hermann, C., Schmidt, B., Peschel, C., Bernhard, H. (2002). Antihuman Epidermal Growth Factor Receptor 2 (HER2) Monoclonal Antibody Trastuzumab Enhances Cytolytic Activity of Class I-restricted HER2-specific T Lymphocytes Against HER2-overexpressing Tumor Cells. Cancer Res. 62: 2244-2247 [Abstract] [Full Text]  
• Jager, E., Salter, R., Castelli, C., Hohn, H., Freitag, K., Karbach, J., Neukirch, C., Necker, A., Knuth, A., Maeurer, M. J. (2002). Impact of Antigen Presentation on TCR Modulation and Cytokine Release: Implications for Detection and Sorting of Antigen-Specific CD8+ T Cells Using HLA-A2 Wild-Type or HLA-A2 Mutant Tetrameric Complexes. J. Immunol. 168: 2766-2772 [Abstract] [Full Text]  
• Alkhateeb, A., Stetler, G. L., Old, W., Talbert, J., Uhlhorn, C., Taylor, M., Fox, A., Miller, C., Dills, D. G., Ridgway, E. C., Bennett, D. C., Fain, P. R., Spritz, R. A. (2002). Mapping of an autoimmunity susceptibility locus (AIS1) to chromosome 1p31.3-p32.2. Hum Mol Genet 11: 661-667 [Abstract] [Full Text]  
• Le Poole, I. C., Riker, A. I., Quevedo, M. E., Stennett, L. S., Wang, E., Marincola, F. M., Kast, W. M., Robinson, J. K., Nickoloff, B. J. (2002). Interferon-{gamma} Reduces Melanosomal Antigen Expression and Recognition of Melanoma Cells by Cytotoxic T Cells. Am. J. Pathol. 160: 521-528 [Abstract] [Full Text]  
• Cordaro, T. A., de Visser, K. E., Tirion, F. H., Schumacher, T. N. M., Kruisbeek, A. M. (2002). Can the Low-Avidity Self-Specific T Cell Repertoire Be Exploited for Tumor Rejection?. J. Immunol. 168: 651-660 [Abstract] [Full Text]  
• Ghadersohi, A., Sood, A. K. (2001). Prostate Epithelium-derived Ets Transcription Factor mRNA Is Overexpressed in Human Breast Tumors and Is A Candidate Breast Tumor Marker and A Breast Tumor Antigen. Clin. Cancer Res. 7: 2731-2738 [Abstract] [Full Text]  
• van Elsas, A., Sutmuller, R. P.M., Hurwitz, A. A., Ziskin, J., Villasenor, J., Medema, J.-P., Overwijk, W. W., Restifo, N. P., Melief, C. J.M., Offringa, R., Allison, J. P. (2001). Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine: Comparison of Prophylaxis and Therapy. JEM 194: 481-490 [Abstract] [Full Text]  
• Meyer zum Buschenfelde, C., Metzger, J., Hermann, C., Nicklisch, N., Peschel, C., Bernhard, H. (2001). The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells. J. Immunol. 167: 1712-1719 [Abstract] [Full Text]  
• Riddell, S. R. (2001). Progress in cancer vaccines by enhanced self-presentation. Proc. Natl. Acad. Sci. USA 98: 8933-8935 [Full Text]  
• Fearon, D. T., Manders, P., Wagner, S. D. (2001). Arrested Differentiation, the Self-Renewing Memory Lymphocyte, and Vaccination. Science 293: 248-250 [Abstract] [Full Text]  
• Kedl, R. M., Jordan, M., Potter, T., Kappler, J., Marrack, P., Dow, S. (2001). CD40 stimulation accelerates deletion of tumor-specific CD8+ T cells in the absence of tumor-antigen vaccination. Proc. Natl. Acad. Sci. USA 98: 10811-10816 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS